Guisado Rasco A, Lage Gallé E, Sobrino Márquez J M, Sánchez Brotons J A, Mogollón Jiménez M V, Borrego Domínguez J M, Martínez Martínez A
Cardiology and Cardiac Surgery Departments, Virgen del Rocio University Hospital, Seville, Spain.
Transplant Proc. 2008 Nov;40(9):3058-9. doi: 10.1016/j.transproceed.2008.09.048.
To evaluate the safety and efficacy of ezetimibe in a sample of transplanted cardiac patients.
We undertook a descriptive retrospective observational study of 19 transplanted cardiac patients in whom treatment with ezetimibe was initiated at doses of 10 mg/d between 2004 and 2006, assessing tolerability and changes in lipid levels (total cholesterol and triglycerides), doses of immunosuppressive drugs, and the hepatic profile after 12 months of treatment.
There was no effect on the doses required of any immunosuppressive drugs. We observed a reduction in cholesterol levels, with a normal distribution (mean +/- standard deviation 26.84 +/- 14 mg/dL) among patients with ezetimibe addition, despite no change in the statin doses. There were no changes in the levels of triglycerides, transaminases, or bilirubin, and no cases of rhabdomyolysis or myalgia. All patients continued to take the drug after 1 year of treatment.
In our sample, the administration of ezetimibe to transplanted cardiac patients for 1 year was associated with a reduction in cholesterol levels by 26.8%. No substantial changes in the doses of immunosuppressive drugs could be attributed to the use of ezetimibe. Tolerance was good, with no need for drug withdrawal in any case.
评估依折麦布在心脏移植患者样本中的安全性和有效性。
我们对19例心脏移植患者进行了描述性回顾性观察研究，这些患者在2004年至2006年间开始接受依折麦布治疗，剂量为10毫克/天，评估耐受性以及血脂水平（总胆固醇和甘油三酯）的变化、免疫抑制药物剂量和治疗12个月后的肝脏情况。
对任何免疫抑制药物的所需剂量均无影响。我们观察到胆固醇水平降低，在加用依折麦布的患者中呈正态分布（均值±标准差为26.84±14毫克/分升），尽管他汀类药物剂量没有变化。甘油三酯、转氨酶或胆红素水平没有变化，也没有横纹肌溶解或肌痛病例。所有患者在治疗1年后继续服用该药物。
在我们的样本中，心脏移植患者服用依折麦布1年，胆固醇水平降低了26.8%。免疫抑制药物剂量没有因使用依折麦布而出现实质性变化。耐受性良好，在任何情况下都无需停药。
